SG11202109522VA - Aromatic derivatives, preparation methods, and medical uses thereof - Google Patents

Aromatic derivatives, preparation methods, and medical uses thereof

Info

Publication number
SG11202109522VA
SG11202109522VA SG11202109522VA SG11202109522VA SG11202109522VA SG 11202109522V A SG11202109522V A SG 11202109522VA SG 11202109522V A SG11202109522V A SG 11202109522VA SG 11202109522V A SG11202109522V A SG 11202109522VA SG 11202109522V A SG11202109522V A SG 11202109522VA
Authority
SG
Singapore
Prior art keywords
preparation methods
medical uses
aromatic derivatives
aromatic
derivatives
Prior art date
Application number
SG11202109522VA
Inventor
Ning Shao
Hongbin Yuan
Ding Wang
Frank Kayser
Original Assignee
Bioardis Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioardis Llc filed Critical Bioardis Llc
Publication of SG11202109522VA publication Critical patent/SG11202109522VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202109522VA 2019-03-05 2020-02-19 Aromatic derivatives, preparation methods, and medical uses thereof SG11202109522VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2019/076926 WO2020177067A1 (en) 2019-03-05 2019-03-05 Aromatic derivatives, preparation methods, and medical uses thereof
PCT/CN2020/075849 WO2020177534A1 (en) 2019-03-05 2020-02-19 Aromatic derivatives, preparation methods, and medical uses thereof

Publications (1)

Publication Number Publication Date
SG11202109522VA true SG11202109522VA (en) 2021-09-29

Family

ID=72337401

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109522VA SG11202109522VA (en) 2019-03-05 2020-02-19 Aromatic derivatives, preparation methods, and medical uses thereof

Country Status (9)

Country Link
US (1) US11976058B2 (en)
EP (1) EP3935048A4 (en)
JP (1) JP7470708B2 (en)
KR (1) KR20210135558A (en)
CN (1) CN111902400A (en)
CA (1) CA3132405A1 (en)
SG (1) SG11202109522VA (en)
TW (1) TW202100514A (en)
WO (2) WO2020177067A1 (en)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2721156B1 (en) 2011-06-16 2016-12-21 Ionis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
KR102163776B1 (en) * 2012-07-11 2020-10-12 블루프린트 메디신즈 코포레이션 Inhibitors of the fibroblast growth factor receptor
AU2014228746B2 (en) 2013-03-15 2018-08-30 Celgene Car Llc Heteroaryl compounds and uses thereof
JP6084292B2 (en) 2013-07-18 2017-02-22 大鵬薬品工業株式会社 FGFR inhibitor resistant cancer therapeutics
AU2014337291B9 (en) 2013-10-18 2020-05-07 Eisai R&D Management Co., Ltd. Pyrimidine FGFR4 inhibitors
ES2682493T3 (en) 2013-10-25 2018-09-20 Novartis Ag Compounds derived from ring-fused bicyclic pyridyl as FGFR4 inhibitors
JP6458023B2 (en) 2013-10-25 2019-01-23 ブループリント メディシンズ コーポレイション Inhibitors of fibroblast growth factor receptor
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
EP3160935B1 (en) 2014-06-24 2021-11-17 Covestro Intellectual Property GmbH & Co. KG Method for producing di- and polyamines of the diphenylmethane series
WO2016064960A1 (en) 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
EP3029864B1 (en) 2014-12-01 2020-11-18 Harman Becker Automotive Systems GmbH Fast representation of station information in a fm receiver using a single tuner
WO2016134294A1 (en) * 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
CN113004278B (en) 2015-02-20 2023-07-21 因赛特控股公司 Bicyclic heterocycles as FGFR inhibitors
CN105906630B (en) 2015-04-06 2018-10-23 四川百利药业有限责任公司 Two substitutional amine-group compounds of N- (1H- pyrazoles -5- bases) pyrimido pyrazoles -4,6- as FGFR inhibitor
WO2016164703A1 (en) 2015-04-09 2016-10-13 Eisai R & D Management Co., Ltd. Fgfr4 inhibitors
CN107286130A (en) 2016-04-13 2017-10-24 成都融科博海科技有限公司 A kind of Kinase Selectivity inhibitor
KR102288281B1 (en) * 2016-12-19 2021-08-10 아비스코 테라퓨틱스 컴퍼니 리미티드 FGFR4 inhibitors, methods for their preparation and pharmaceutical applications
JP7346420B2 (en) * 2017-09-05 2023-09-19 バイオアーディス エルエルシー Aromatic derivatives, their preparation methods and their medical applications
CN109224235B (en) 2018-10-23 2020-05-19 孙喜家 Double-cavity tube
CN109331654A (en) 2018-10-26 2019-02-15 高邮高和光电器材有限公司 A kind of organic exhaust gas photocatalytic oxidation device

Also Published As

Publication number Publication date
KR20210135558A (en) 2021-11-15
EP3935048A1 (en) 2022-01-12
JP2022522890A (en) 2022-04-20
US20220169634A1 (en) 2022-06-02
CN111902400A (en) 2020-11-06
US11976058B2 (en) 2024-05-07
WO2020177534A1 (en) 2020-09-10
JP7470708B2 (en) 2024-04-18
CA3132405A1 (en) 2020-09-10
EP3935048A4 (en) 2022-11-09
TW202100514A (en) 2021-01-01
WO2020177067A1 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
EP3546457A4 (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
EP3725798A4 (en) Bioactive conjugate, preparation method therefor and use thereof
EP3733715A4 (en) Triabody, preparation method and use thereof
EP3907218A4 (en) 6-oxo-1,6-dihydropyridazine derivative, preparation method therefor and medical use thereof
SG11202005962YA (en) Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application
EP3636646A4 (en) Heteroaryl-pyrazole derivative, and preparation method therefor and medical application thereof
EP3479841A4 (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
EP3967687A4 (en) Substituted phenylpropenylpyridine derivative, and preparation method therefor and medical use thereof
EP3248963A4 (en) Pyrrole sulfonyl derivative, and preparation method and medical use thereof
EP3517535A4 (en) Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof
EP3385262A4 (en) Protein kinase inhibitor, preparation method and medical use thereof
EP3569596A4 (en) 1,2,4-triazine-3-amine derivative, preparation method therefor, and use thereof in medicine
EP3400031A4 (en) Human placental tissue graft products, methods, and apparatuses
EP3261501A4 (en) Soft, strong and bulky tissue
IL276952A (en) 2,4-diaminoquinazoline derivatives and medical uses thereof
EP3663293A4 (en) Substituted penta- and hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof
EP3395809A4 (en) Benzopiperidine derivative, preparation method thereof and medical use thereof
EP3919489A4 (en) Aromatic ring or heteroaromatic ring compounds, preparation method therefor and medical use thereof
EP3144292A4 (en) 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, preparation method therefor and medicinal use thereof
EP3590941A4 (en) Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof
EP3822271A4 (en) Pyridopyrimidine derivative, preparation method therefor and medical use thereof
EP3398958A4 (en) Polyaminoacid, protein-polyaminoacid conjugate and preparation method therefor
EP4063363A4 (en) Pyrazolo-heteroaryl derivative, preparation method therefor, and medical use thereof
EP3556761A4 (en) Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof
EP3530657A4 (en) 2-polysubstituted aromatic ring-pyrimidine derivative and preparation and medical use